Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: Analysis of prognostic factors and comparison with a single procedure

References

• Linch D C, Winfield D, Goldstone A H, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Horning S J, Chao N J, Negrin R S, Hoppe R T, Long G D, Hu W W, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Pico J L, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222–229
   PubMed Web of Science ®Google Scholar
• Yuen A R, Rosenberg S A, Hoppe R T, Halpern J D, Horning S J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Sweetenham J W, Carella A M, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101–3109
   PubMed Web of Science ®Google Scholar
• Sweetenham J W, Taghipour G, Milligan D, Blystad A K, Caballero D, Fassas A, Goldstone A H. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 745–752
   PubMed Web of Science ®Google Scholar
• Josting A, Engert A, Diehl V, Canellos G P. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol 2002; 13(Suppl 1)112–116
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M, Glossmann J P, Sienawski M, Sieber M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116–123
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder R F, Piantadosi S, Abrams R A, Brodsky R A, Vogelsang G B, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314–4321
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta J J, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, Arranz R, Caballero M D, Vidal M J, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625–633
   PubMed Web of Science ®Google Scholar
• Constans M, Sureda A, Terol M J, Arranz R, Caballero M D, Iriondo A, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14: 745–751
   PubMed Web of Science ®Google Scholar
• Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004; 15: 1222–1230
   PubMed Web of Science ®Google Scholar
• Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Gozdzik J, Holowiecki J, et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002; 30: 29–34
   PubMed Web of Science ®Google Scholar
• Lavoie J C, Connors J M, Phillips G L, Reece D E, Barnett M J, Forrest D L, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473–1478
   PubMed Web of Science ®Google Scholar
• Josting A, Nogova L, Franklin J, Glossmann J P, Eich H T, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23: 1522–1529
   PubMed Web of Science ®Google Scholar
• Wirth A, Corry J, Laidlaw C, Matthews J, Liew K H. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997; 39: 599–607
   PubMed Web of Science ®Google Scholar
• Milpied N, Fielding A K, Pearce R M, Ernst P, Goldstone A H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291–1296
   PubMed Web of Science ®Google Scholar
• Schmitz N, Sureda A, Robinson S. Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results. Semin Oncol 2004; 31: 27–32
   PubMed Web of Science ®Google Scholar
• Carella A M, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924
   PubMed Web of Science ®Google Scholar
• Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999; 10: 1485–1488
   PubMed Web of Science ®Google Scholar
• Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J, et al. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 2004; 33: 1225–1229
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci M L, Bibi Triki T, et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 747–755
   PubMed Web of Science ®Google Scholar
• Lin T S, Avalos B R, Penza S L, Marcucci G, Elder P J, Copelan E A. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002; 29: 763–767
   PubMed Web of Science ®Google Scholar
• Ahmed T, Lake D E, Beer M, Feldman E J, Preti R A, Seiter K, et al. Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplant 1997; 19: 449–454
   PubMed Web of Science ®Google Scholar